Key result
Circulating blood biomarkers may be beneficial in better elucidating the pathophysiology, development, progression, and therapeutic efficacy in the management of hypertension.
Why the study?
In over 90% of hypertensive patients, the cause of blood pressure elevation is unknown, highlighting the need for biomarkers to improve early diagnosis and management.
Circulating blood biomarkers may offer a novel and robust approach for understanding the pathophysiology and improving the diagnosis and management of hypertension.
Novel lab approaches may refine essential hypertension diagnosis; leaves open need for prospective validation before practice change.
Hypertension remains one of the most significant causes of mortality, affecting more than 1 billion people worldwide. It is a significant public health concern and a major risk factor for renal disease, heart failure, stroke, coronary artery disease and peripheral vascular disease. In more than 90% of hypertensive patients, the cause of blood pressure elevation is unknown. Therefore, early diagnosis and timely interventions are crucial to prevent complications. Over the last four decades, various blood biomarkers have been identified, which can help in understanding the cause of the underlying processes involved in the onset, development and progression of hypertension (HT). It is our attempt, in this review, to suggest a more robust use of circulating biomarkers that may prove to be beneficial in better elucidating the pathophysiology, development, progression and therapeutic efficacy in the management of HT.
No takes yet. Share an insight, caveat, or question.
Bhargava et al. (2022) conducted a review in Hypertension. Circulating biomarkers was evaluated. Circulating blood biomarkers may be beneficial in better elucidating the pathophysiology, development, progression, and therapeutic efficacy in the management of hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: